Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5528-32. doi: 10.1016/j.bmcl.2008.09.003. Epub 2008 Sep 6.

Optimization of a series of potent and selective ketone histone deacetylase inhibitors.

Author information

1
IRBM/Merck Research Laboratories, Via Pontina km 30,600, 00040 Pomezia, Italy. giovanna_pescatore@merck.com

Abstract

Histone deacetylase (HDAC) inhibitors offer a promising strategy for cancer therapy and the first generation HDAC inhibitors are currently in the clinic. Herein we describe the optimization of a series of ketone small molecule HDAC inhibitors leading to potent and selective class I HDAC inhibitors with good dog PK.

PMID:
18809328
DOI:
10.1016/j.bmcl.2008.09.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center